Replimune Group, which is developing oncolytic immunotherapies to fight solid tumors, raised $101 million by offering 6.7 million shares at $15, within the range of $14 to $16. Replimune Group plans to list on the Nasdaq under the symbol REPL. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as lead managers on the deal.
